메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

TS Financial Holding's TS SmartBrain Recognized for Driving Intelligent Financial Services

SHANGHAI, Jan. 19, 2026 -- TS Financial Holding Co., Ltd. has been recognized under the Service and Solution category at the International Innovation Awards (IIA) 2025, organized by Enterprise Asia, for TS SmartBrain, an enterprise-level large language model developed in-house to support secure and intelligent digital transformation within the financial sector. Purpose-built for high compliance environments, TS SmartBrain operates entirely within a fully controlled, on-premise infrastructure. This ensures that all model training and inference activities remain aligned with stringent da
- 황정호 기자
- 2026-01-19 10:59
WeLab completes US$220 million Series D strategic financing, marking the largest digital banking capital raise in Asia in 2025

HONG KONG, Jan. 19, 2026 -- WeLab, a leading pan-Asian fintech platform, announced the successful closing of its Series D strategic financing, securing US$220 million in funding. This marks the largest digital banking capital raise in Asia for 2025 and the largest funding round since WeLab's inception, demonstrating strong investor confidence in WeLab's vision and scalable growth trajectory. The financing round, comprising both debt and equity, secured investment from a diverse array of new investors, alongside strong support from existing investors and strategic capital partners, incl
- 황정호 기자
- 2026-01-19 10:06
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

SHANGHAI, Jan. 19, 2026 -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 — a KRAS G12D inhibitor — enabling the start of a Phase 1 first‑in‑human clinical trial. A Phase 2 combination trial evaluating D3S‑001 (elisrasib), the Company's next‑generation KRAS G12C inhibitor, in combination with D3S‑002, a selective oral ERK1/2 inhibitor. D3S‑003 is an ora
- 김갑성 기자
- 2026-01-19 09:00
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 19, 2026 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1
- 김갑성 기자
- 2026-01-19 08:02
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership

SHANGHAI, Jan. 19, 2026 -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP's highest rating in each category, underscores WuXi AppTec's achievements in climate change and water resource management and its ongoing commitment to sustainable development. CDP is a global non-pro
- 김갑성 기자
- 2026-01-19 08:00
A Smarter New Year's Resolution: Investing in Eye Comfort for Screen Heavy Workdays

SYDNEY, Jan. 19, 2026 -- As the new year begins, many Australians are setting resolutions focused on health, balance and long-term wellbeing. While fitness goals and productivity upgrades often dominate the conversation, eye comfort during extended screen use is frequently overlooked. With work, communication and entertainment increasingly centred around screens, visual fatigue has become a common challenge, particularly for those spending long hours at a desk. Improving the environment around the screen is a practical way to support healthier work habits throughout the year. &n
- 김갑성 기자
- 2026-01-19 08:00
Elliott Opposes Toyota Fudosan's Revised Tender Offer for Toyota Industries Corporation

Elliott, the largest independent shareholder of Toyota Industries, believes the revised tender offer very significantly undervalues the Company and does not intend to tender its shares LONDON, Jan. 19, 2026 -- Elliott Investment Management L.P. and Elliott Advisors (UK) Limited ("Elliott"), which advise funds that together have a significant ownership stake in Toyota Industries Corporation ("Toyota Industries" or the "Company"), today published an open letter to the Company's shareholders. In the letter, Elliott outlined its oppositi
- 황정호 기자
- 2026-01-19 07:30
エリオットはトヨタ不動産による豊田自動織機に対する改定後の公開買付けに反対いたします

豊田自動織機の最大の独立した株主であるエリオットは、改定後の公開買付けは豊田自動織機を著しく過小評価していると確信しており、保有する株式を応募する意向はありませんロンドン, 2026年1月19日 -- Elliott Investment Management, L.P.およびElliott Advisors (UK) Limited（以下「エリオット」または「当社」）は、株式会社豊田自動織機（以下「豊田自動織機」または「同社」）の株式を相当額保有する大株主であるファンドに助言を行っております。当社は当該ファンドを代表し、豊田自動織機の株主の皆様宛てに、以下の公開書簡を本日公表しました。エリオットは、本公開書簡において、トヨタ不動産株式会社が提示した一株あたり18,800円の改定後の公開買付け（以下「本改定後TOB」）に反対の立場を明らかにしました。エリオットは、本改定後TOB価格は、豊田自動織機を著しく過小評価していると確信しています。エリオットの分析によれば、豊田自動織機の本源的な純資産価値は2026年1月16日時点で一株あたり26,000円超に達しており、これは本改定後TOB価格をほぼ40%上回る水準です。さらに、豊田自動織機が独立して成長を遂げることを前提としたスタンドアローン・プランは、同社の価値が2028
- 황정호 기자
- 2026-01-19 07:30
Taptouch Introduces Australia's First Locally Built Embedded Payments POS

SYDNEY, Jan. 19, 2026 -- Taptouch Software, an Australian-owned hospitality POS provider, today announced the launch of its embedded payment solution (Tap to Pay), fully integrated into its point-of-sale platform. While embedded payment technology is gaining traction globally, Taptouch is the first Australian-owned POS provider to deliver fully embedded payments designed specifically for hospitality operations. The new embedded Tap-to-Pay capability allows cafes, restaurants, pubs, bars, and hotels to accept contactless cards and digital wallets — including Apple Pay and Google Pay — d
- 황정호 기자
- 2026-01-19 06:00
데저트 X 알울라 2026: 고대 오아시스 알울라에서 대규모 대지 미술 전시 개막

[ 메디채널 김장윤(JASON KIM) 기자 ] 알울라, 사우디아라비아, 2026년 1월 18일 -- 국제 야외 비엔날레 전시회의 획기적인 네 번째 전시인 데저트 X 알울라 2026(Desert X AlUla 2026)이 1월 15일 공식 개막했다. 아츠 알울라(Arts AlUla)가 데저트 X(Desert X)와 공동으로 기획한 이번 전시는 사우디아라비아 내 예술가를 비롯해 여러 세대에 걸친 해외 유명 예술가들을 초빙해 화려한 라인업으로 꾸려졌다. 알울라의 경이로운 풍경 속에서 이들의 장소 맞춤형 대지 미술과 조각•설치 미술 작품들이 층층이 쌓인 유산과 어우러져 환상적인 예술적 하모니를 선사할 예정이다. 사우디아라비아 북서부에 위치한 알울라는 고대 역사와 숨 막히는 자연 경관을 자랑하는 최고의 미술 무대로, 지역 최초의 공공 예술 비엔날레이자 알울라 아츠 페스티벌(AlUla Arts Festival)의 하이라이트인 데저트 X 알울라를 통해 글로벌 무대에서 역동적인 신흥 대지 미술 거점으로서의 위상을 떨치고 있다. 데저트 X 알울라 2026년 전시는 아이디어, 재료 및 전통의 경계를 넘나들며 다양한 작품을 선보이는
- 김장윤(JASON KIM) 기자
- 2026-01-19 00:38

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-19_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 19일 21시 00분